The acquisition enhances the portfolio of Aditxt in precision diagnostics and infectious disease treatment. Credit: Gorodenkoff / Shutterstock.com.

Aditxt has announced a definitive agreement under which its subsidiary, Adivir, will acquire complete issued and outstanding Class A common shares of biopharmaceutical company Appili Therapeutics.

The move enhances Aditxt’s portfolio and creates synergies with its existing programmes, particularly in precision diagnostics.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Founded in 2015, Appili developed the Food and Drug Administration-approved LIKMEZ (ATI-1501).

LIKMEZ is a reformulated version of the antibiotic metronidazole that improves patient experience and compliance by making the medication easier to swallow and better tasting.

Appili licensed the manufacturing and commercialisation rights of the product in the US and other selected territories to Saptalis Pharmaceuticals.

Appili is also advancing ATI-1701, a live attenuated vaccine for Francisella tularensis.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The US Department of Defense has supported the ATI-1701 biodefence programme with $14m non-dilutive funding to progress the vaccine’s development.

Another key asset in Appili’s portfolio is ATI-1801, a topical formulation for cutaneous leishmaniasis.

The product, which contains paromomycin, offers a more patient-friendly treatment option for this painful and disfiguring disease.

The acquisition will aid Aditxt in bolstering its portfolio and integrating precision diagnostics with tailored treatment strategies.

The closure of the acquisition will occur in the third quarter of 2024.

Aditxt co-founder, chairman and CEO Amro Albanna stated: “The acquisition of Appili would represent another step in Aditxt’s journey towards advancing promising innovations in health.

“Our mission is to accelerate some of the most promising health innovations, like those developed by Appili, to reach their full potential and to have a lasting impact.

“By integrating Appili’s proven expertise and diverse portfolio in the infectious disease and biodefence domain, Aditxt can substantially contribute to advancing public health solutions.”